Brief: Heidelberg Pharma AG Sees FY22 Sales And Other Income Between EUR 18.5 Mln And EUR 20.5 Mln
04/10/2022 16:55
Oct 4 (Reuters) - Heidelberg Pharma AG HPHA.DE :
* EQS-ADHOC: HEIDELBERG PHARMA AG ANNOUNCES ADJUSTMENT OF
GUIDANCE
* HEIDELBERG PHARMA AG - CO EXPECTS FOR FINANCIAL YEAR 2022
SALES
AND OTHER INCOME BETWEEN EUR 18.5 MILLION AND EUR 20.5 MILLION
* HEIDELBERG PHARMA - SEES FY 2022 OPERATING RESULT (EBIT)
BETWEEN
EUR -16.0 MILLION AND EUR -20.0 MILLION (PREVIOUSLY: EUR -32.5
MILLION TO EUR -36.5 MILLION)
Source text for Eikon: ID:nEQ9Dq6FZa
Further company coverage: HPHA.DE
((Reuters.Brief@thomsonreuters.com;))
Recent news on Heidelberg Pharma AG
See all newsBrief: Heidelberg Pharma Says Co. And Healthcare Royalty Announce Amendment To Existing Royalty Agreement
Brief: Redhill Biopharma Secures Allowance Of Key Chinese Patent Application For Proprietary COVID-19 Treatment, RHB-107
Brief: Heidelberg Pharma Amends Royalty Financing With Healthcare Royalty
Brief: Heidelberg Pharma Expects FY EBIT Between EUR -19 Mln And EUR -22 Mln
Brief: Heidelberg Pharma AG: Announces Updated Guidance